With your own knowledge and the help of the following document:

Document 1 (Title: Anticoagulation Therapy in Trauma Settings): Trauma patients represent a complex population with multiple competing priorities in clinical management. Hemorrhage control remains a cornerstone of trauma care, with coagulopathy frequently complicating initial presentations. Multiple studies have documented significant increases in mortality when anticoagulant therapy is administered during active bleeding phases. Recent retrospective analyses examining 1,248 trauma patients demonstrated a 3.5-fold increase in adverse outcomes when therapeutic anticoagulation was initiated prior to hemorrhage control confirmation. Case series have consistently demonstrated prolonged bleeding, increased transfusion requirements, and higher intervention rates when standard anticoagulation protocols were followed in trauma contexts. Clinical guidelines now emphasize the critical importance of delayed anticoagulation until hemostatic stability is confirmed, with consensus recommendations focusing on mechanical prophylaxis during initial stabilization periods. The documented complications of early anticoagulation in trauma settings have prompted reevaluation of traditional venous thromboembolism protocols, with increasing evidence suggesting modifications to standard approaches are necessary for this vulnerable population. While prophylactic anticoagulation remains important for immobilized trauma patients, therapeutic dosing continues to demonstrate concerning safety profiles in multiple trauma registries.
Document 2 (Title: Emergent Interventions for Limb-Threatening Ischemia): Acute limb ischemia represents a vascular emergency requiring rapid assessment and intervention to prevent permanent tissue damage and limb loss. The condition results from sudden interruption of arterial blood flow, most commonly due to embolism or thrombosis, with the lower extremities affected more frequently than upper extremities. Cardioembolic events account for approximately 80% of acute arterial emboli, with atrial fibrillation representing the predominant cardiac source. The clinical presentation follows the classic six Ps of ischemia: pain, pallor, pulselessness, paresthesia, paralysis, and poikilothermia (cold). Neurological manifestations—paresthesia and paralysis—represent particularly ominous signs indicating advanced ischemia with tissue compromise. Initial management focuses on preventing thrombus propagation and establishing definitive revascularization. Immediate systemic anticoagulation with unfractionated heparin constitutes the critical first therapeutic intervention, ideally administered as an intravenous bolus followed by continuous infusion titrated to therapeutic aPTT levels. This prevents thrombus propagation while diagnostic and therapeutic planning proceeds. Antiplatelet therapy with aspirin provides modest complementary benefit but should not delay anticoagulation. Revascularization options include surgical thromboembolectomy and endovascular approaches such as catheter-directed thrombolysis. Tissue plasminogen activator, while effective for cerebral ischemia within its narrow therapeutic window, carries excessive bleeding risk in peripheral arterial occlusion and requires longer infusion periods incompatible with limb salvage timeframes. The choice between surgical and endovascular approaches depends on ischemia severity, anatomic considerations, patient comorbidities, and institutional expertise, with surgery generally preferred for advanced ischemia.
Document 3 (Title: Antithrombotic Properties of Acetylsalicylic Acid): Aspirin represents a fundamental antithrombotic agent with distinctive pharmacological properties determining its clinical applications and management considerations in cardiovascular disease prevention. Multiple randomized clinical trials have demonstrated significant efficacy in secondary prevention following myocardial infarction, with meta-analyses documenting approximately 25% reduction in recurrent events through platelet inhibition mechanisms. This established benefit has positioned aspirin as a cornerstone therapy in comprehensive secondary prevention protocols following acute coronary syndromes. Mechanistic investigations reveal that aspirin's antiplatelet effects result from irreversible acetylation of cyclooxygenase-1 (COX-1) serine residues rather than interactions with glycoprotein IIb/IIIa receptors, which are targeted by alternative antiplatelet agents including abciximab and tirofiban. The irreversible nature of this enzymatic inhibition explains aspirin's prolonged pharmacodynamic effects despite its relatively short pharmacokinetic half-life, with platelet functional recovery requiring new platelet production over 7-10 days rather than following 6-hour elimination patterns. Clinical pharmacology studies demonstrate important interactions with concurrent anticoagulant therapy, with aspirin enhancing the antithrombotic effects of vitamin K antagonists through complementary mechanisms potentially increasing bleeding risk without affecting INR measurements. Dosing considerations reveal that anti-thrombotic efficacy requires significantly lower doses than anti-inflammatory applications, with optimal platelet inhibition typically achieved with daily doses between 75-150 mg rather than the higher doses exceeding 500 mg daily required for analgesic and anti-inflammatory effects. This dose separation explains aspirin's favorable safety profile in cardiovascular applications compared to full anti-inflammatory dosing regimens, though still requiring appropriate patient selection and risk-benefit assessment.

Answer the following true/false question.
Question: Therapeutic anticoagulation in the trauma patient: is it safe?
Options:
A. True
B. False

Please respond **only** with a single valid JSON object in the following format:
{"answer": "True"}  ← if the answer is true
{"answer": "False"} ← if the answer is false
Do not include any other text or comments. Output must be strictly JSON.